scholarly journals A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease

2018 ◽  
Vol 63 (2) ◽  
pp. 783-796 ◽  
Author(s):  
Enrico R. Fantoni ◽  
Anastasia Chalkidou ◽  
John T. O’ Brien ◽  
Gill Farrar ◽  
Alexander Hammers
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Imaging ◽  
Amyloid Pet ◽  
Diagnostic Confidence ◽  
The Impact

scholarly journals The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia

Metabolites ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 380
Author(s):  
Seunghee Na ◽  
Hyeonseok Jeong ◽  
Jong-Sik Park ◽  
Yong-An Chung ◽  
In-Uk Song
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Amyloid Beta ◽  
Neuropsychiatric Symptoms ◽  
Amyloid Pet ◽  
Motor Symptoms ◽  
Parkinson’S Disease Dementia ◽  
The Impact

The neuropathology of Parkinson’s disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer’s disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer’s disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.

scholarly journals Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

2015 ◽  
Vol 43 (2) ◽  
pp. 374-385 ◽  
Author(s):  
Elizabeth Morris ◽  
Anastasia Chalkidou ◽  
Alexander Hammers ◽  
Janet Peacock ◽  
Jennifer Summers ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Diagnostic Accuracy ◽  
Meta Analysis ◽  
Amyloid Pet ◽  
Pet Tracers

scholarly journals C-15 Serotonergic System Activity and BPSD in Alzheimer’s Disease Pathogenesis: A Systematic Review

2019 ◽  
Vol 34 (6) ◽  
pp. 1044-1044 ◽  
Author(s):  
J Lennon ◽  
B Sytsma ◽  
A Mohit ◽  
S Patel
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonergic System ◽  
Data Selection ◽  
Pharmacological Intervention ◽  
Ongoing Research ◽  
Recurrent Seizure ◽  
Visual Spatial ◽  
The Impact

Abstract Objective The 5-hydroxytryptamine (5-HT) system is heavily implicated in behavioral and psychological symptoms of dementia (BPSD), with substantial bases for ongoing research in Alzheimer’s disease (AD). This system is directly tied to the hypothalamic-pituitary-adrenal axis. This systematic review aims to accomplish the following objectives: 1) introduce noteworthy BPSD found in AD; 2) synthesize research on 5-HT and BPSD in AD; 3) discuss neuropsychological sequelae of serotonergic dysregulation in AD; and, 4) report future research directions. Data Selection Data Selection: We conducted a literature search of the Medline, PubMed, psychINFO, and Google Scholar databases using the following keywords: Alzheimer’s*, seroton* (serotonin, serotonergic), 5-HT* (5-HTR, 5-HTT*), neuropsychology, behavior*, cogniti*. From the list of studies obtained through this search, we then employed the following inclusion criteria: 1) individuals in study had a formal diagnosis of probable or suspected AD; 2) individuals in study had not previously experienced head trauma, recurrent seizure, or other neurological insult; 3) sample did not include participants with comorbid personality disorders. Data Synthesis Findings suggest that serotonin’s receptors (5-HTRs), transporter (5-HTT), metabolite (5-HTP), and transporter-linked polymorphic region (5-HTTLPR) are linked to depression, anxiety, hyperactivity/impulsivity, aggression, and apathy in AD. Further, 5-HT and resultant BPSD are implicated in numerous cognitive functions including but not limited to decision-making, visual-spatial deficits, attention and vigilance, episodic memory, global cognitive function. Conclusions Substantial evidence exists implicating the serotonergic system in BPSD in AD. By understanding the impact of 5-HT on disease trajectory, neurocognitive functioning, and neuropsychological test performance, clinicians can ensure that appropriate recommendations are made for psychosocial and pharmacological intervention.

scholarly journals P3-618: THE IMPACT OF FOOD PROVISION STUDIES ON ALZHEIMER'S DISEASE: A SYSTEMATIC REVIEW

2019 ◽  
Vol 15 ◽  
pp. P1214-P1214
Author(s):  
Joseph Martinez ◽  
Juanita A. Draime ◽  
Julia C. Gardner ◽  
Sarah E. Berman ◽  
Aleda M.H. Chen
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Food Provision ◽  
The Impact

scholarly journals The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study

2017 ◽  
Vol 13 (9) ◽  
pp. 1013-1023 ◽  
Author(s):  
Paolo Bosco ◽  
Alberto Redolfi ◽  
Martina Bocchetta ◽  
Clarissa Ferrari ◽  
Anna Mega ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Diagnostic Confidence ◽  
The Impact

scholarly journals Speech- and Language-Based Classification of Alzheimer’s Disease: A Systematic Review

2022 ◽  
Vol 9 (1) ◽  
pp. 27
Author(s):  
Inês Vigo ◽  
Luis Coelho ◽  
Sara Reis
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Best Practices ◽  
Early Stage ◽  
Low Cost ◽  
Clinical Stage ◽  
Invasive Procedure ◽  
The Impact

Background: Alzheimer’s disease (AD) has paramount importance due to its rising prevalence, the impact on the patient and society, and the related healthcare costs. However, current diagnostic techniques are not designed for frequent mass screening, delaying therapeutic intervention and worsening prognoses. To be able to detect AD at an early stage, ideally at a pre-clinical stage, speech analysis emerges as a simple low-cost non-invasive procedure. Objectives: In this work it is our objective to do a systematic review about speech-based detection and classification of Alzheimer’s Disease with the purpose of identifying the most effective algorithms and best practices. Methods: A systematic literature search was performed from Jan 2015 up to May 2020 using ScienceDirect, PubMed and DBLP. Articles were screened by title, abstract and full text as needed. A manual complementary search among the references of the included papers was also performed. Inclusion criteria and search strategies were defined a priori. Results: We were able: to identify the main resources that can support the development of decision support systems for AD, to list speech features that are correlated with the linguistic and acoustic footprint of the disease, to recognize the data models that can provide robust results and to observe the performance indicators that were reported. Discussion: A computational system with the adequate elements combination, based on the identified best-practices, can point to a whole new diagnostic approach, leading to better insights about AD symptoms and its disease patterns, creating conditions to promote a longer life span as well as an improvement in patient quality of life. The clinically relevant results that were identified can be used to establish a reference system and help to define research guidelines for future developments.

scholarly journals Transfer Learning for Alzheimer’s Disease through Neuroimaging Biomarkers: A Systematic Review

Sensors ◽  
2021 ◽  
Vol 21 (21) ◽  
pp. 7259
Author(s):  
Deevyankar Agarwal ◽  
Gonçalo Marques ◽  
Isabel de la Torre-Díez ◽  
Manuel A. Franco Martin ◽  
Begoña García Zapiraín ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Deep Learning ◽  
Transfer Learning ◽  
Future Research ◽  
Amyloid Pet ◽  
Learning Models ◽  
Neuroimaging Biomarkers ◽  
Prognostic Prediction

Alzheimer’s disease (AD) is a remarkable challenge for healthcare in the 21st century. Since 2017, deep learning models with transfer learning approaches have been gaining recognition in AD detection, and progression prediction by using neuroimaging biomarkers. This paper presents a systematic review of the current state of early AD detection by using deep learning models with transfer learning and neuroimaging biomarkers. Five databases were used and the results before screening report 215 studies published between 2010 and 2020. After screening, 13 studies met the inclusion criteria. We noted that the maximum accuracy achieved to date for AD classification is 98.20% by using the combination of 3D convolutional networks and local transfer learning, and that for the prognostic prediction of AD is 87.78% by using pre-trained 3D convolutional network-based architectures. The results show that transfer learning helps researchers in developing a more accurate system for the early diagnosis of AD. However, there is a need to consider some points in future research, such as improving the accuracy of the prognostic prediction of AD, exploring additional biomarkers such as tau-PET and amyloid-PET to understand highly discriminative feature representation to separate similar brain patterns, managing the size of the datasets due to the limited availability.

The impact of alcohol on Alzheimer's disease: A systematic review

2013 ◽  
Vol 17 (2) ◽  
pp. 133-146 ◽  
Author(s):  
Anna K. Piazza-Gardner ◽  
Timothy J.B. Gaffud ◽  
Adam E. Barry
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Impact

scholarly journals The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis

2016 ◽  
Vol 43 (S1) ◽  
pp. S51-S82 ◽  
Author(s):  
Kirsten M. Fiest ◽  
Jodie I. Roberts ◽  
Colleen J. Maxwell ◽  
David B. Hogan ◽  
Eric E. Smith ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Diagnostic Criteria ◽  
Full Text ◽  
Data Extraction ◽  
Meta Analysis ◽  
Community Settings ◽  
Healthcare Needs ◽  
The Impact

AbstractBackgroundUpdated information on the epidemiology of dementia due to Alzheimer’s disease (AD) is needed to ensure that adequate resources are available to meet current and future healthcare needs. We conducted a systematic review and meta-analysis of the incidence and prevalence of AD.MethodsThe MEDLINE and EMBASE databases were searched from 1985 to 2012, as well as the reference lists of selected articles. Included articles had to provide an original population-based estimate for the incidence and/or prevalence of AD. Two individuals independently performed abstract and full-text reviews, data extraction and quality assessments. Random-effects models were employed to generate pooled estimates stratified by age, sex, diagnostic criteria, location (i.e., continent) and time (i.e., when the study was done).ResultsOf 16,066 abstracts screened, 707 articles were selected for full-text review. A total of 119 studies met the inclusion criteria. In community settings, the overall point prevalence of dementia due to AD among individuals 60+ was 40.2 per 1000 persons (CI95%: 29.1-55.6), and pooled annual period prevalence was 30.4 per 1000 persons (CI95%: 15.6-59.1). In community settings, the overall pooled annual incidence proportion of dementia due to AD among individuals 60+ was 34.1 per 1000 persons (CI95%: 16.4-70.9), and the incidence rate was 15.8 per 1000 person-years (CI95%: 12.9-19.4). Estimates varied significantly with age, diagnostic criteria used and location (i.e., continent).ConclusionsThe burden of AD dementia is substantial. Significant gaps in our understanding of its epidemiology were identified, even in a high-income country such as Canada. Future studies should assess the impact of using such newer clinical diagnostic criteria for AD dementia such as those of the National Institute on Aging–Alzheimer’s Association and/or incorporate validated biomarkers to confirm the presence of Alzheimer pathology to produce more precise estimates of the global burden of AD.

Sign in / Sign up

Export Citation Format

Share Document